查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1668193

急性偏头痛药物市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、给药途径、配销通路、地区和竞争进行细分，2020-2030 年预测

Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球急性偏头痛药物市场价值为 23.5 亿美元，预计在预测期内将持续增长，到 2030 年的年复合成长率(CAGR) 为 4.80%。 该市场是製药行业中的关键部分，专注于满足偏头痛患者的紧急医疗需求 偏头痛是一种令人呕吐、令人衰弱和呕吐系统的神经疾病，伴随着其严重性影响。它包括一系列旨在缓解偏头痛发作期间的症状并减少其復发的药物解决方案。

市场概况
预测期 2026-2030
2024 年市场规模 23.5 亿美元
2030 年市场规模 31.2 亿美元
2025-2030 年复合年增长率 4.80％
成长最快的领域 预防
最大的市场 北美洲

主要市场驱动因素：

主要市场挑战：

主要市场趋势：

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：急性偏头痛药物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗（预防、缓解疼痛）
    • 依给药途径（口服、注射、鼻腔喷雾、其他）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美急性偏头痛药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲急性偏头痛药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区急性偏头痛药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲急性偏头痛药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲急性偏头痛药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章：全球急性偏头痛药物市场：SWOT 分析

第 14 章：竞争格局

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 17586

The global Acute Migraine Drugs Market was valued at USD 2.35 billion in 2024 and is projected to experience consistent growth during the forecast period, with a compound annual growth rate (CAGR) of 4.80% through 2030. This market represents a critical segment within the pharmaceutical industry, focusing on addressing the immediate medical needs of individuals suffering from migraines-a debilitating neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, and light sensitivity. It includes a range of pharmaceutical solutions designed to alleviate symptoms during migraine episodes and reduce their recurrence.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.35 Billion
Market Size 2030USD 3.12 Billion
CAGR 2025-20304.80%
Fastest Growing SegmentPreventive
Largest MarketNorth America

Key Market Drivers:

1. Increasing Global Prevalence of Migraine: The rising global prevalence of migraine is a major driver of growth in the Global Acute Migraine Drugs Market. Between 1990 and 2021, the global migraine burden increased significantly, with prevalence rising by 58.15%, from 732.56 million to 1.16 billion cases. The incidence rate also climbed by 42.06%, signaling a notable surge in newly diagnosed cases. Furthermore, Disability-Adjusted Life Years (DALYs) linked to migraines increased by 58.27%, highlighting the growing health and economic burden of the condition worldwide. This surge points to an expanding market opportunity for acute migraine treatments as pharmaceutical companies and healthcare providers address the increasing demand for effective solutions. As the number of migraine sufferers grows, the demand for fast-acting and specialized treatments rises correspondingly. Migraines are among the most common neurological disorders, affecting millions globally, and are recognized as one of the leading causes of disability, according to health organizations such as the World Health Organization (WHO) and the Global Burden of Disease Study. The rising number of patients seeking treatment is directly contributing to the expanding market for acute migraine drugs, with both prescription and over-the-counter (OTC) medications seeing increased sales and revenue potential. The growing prevalence is not limited to specific demographics, as it spans across various age groups and regions, offering new opportunities for pharmaceutical companies.

Key Market Challenges:

1. Regulatory Barriers and Stringent Approval Processes: Regulatory approvals are essential for ensuring patient safety but can also present challenges in the development and commercialization of new migraine drugs. Regulatory agencies like the FDA and EMA impose strict criteria, requiring extensive clinical trials, meticulous data collection, and significant time and resource investment. The extended approval timelines can delay the market introduction of innovative migraine treatments, limiting patient access to potentially improved options and impacting pharmaceutical companies' revenue streams. To address this, companies must adopt proactive engagement strategies with regulatory bodies, such as early communication, well-designed clinical trials, and thorough data collection efforts to expedite the approval process.

Key Market Trends:

1. Personalized Medicine and Targeted Therapies: Personalized medicine is transforming the migraine treatment landscape by tailoring therapies to individual patient profiles, taking into account genetic, lifestyle, and clinical factors. Targeted therapies address the underlying mechanisms of migraine attacks, improving treatment efficacy and minimizing adverse effects, thereby enhancing patient outcomes. This trend meets growing patient demand for more effective solutions and drives innovation and market expansion. Pharmaceutical companies are investing in research to identify biomarkers and genetic factors linked to migraine susceptibility, leading to the development of drugs with precise mechanisms of action that offer personalized treatment options for patients.

Key Market Players:

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • GlaxoSmithKline PLC
  • Astellas Pharma Inc.
  • Amgen Inc.
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc.

Report Scope: The Global Acute Migraine Drugs Market has been segmented as follows, along with detailed industry trends:

By Treatment:

  • Preventive
  • Pain Relieving

By Route of Administration:

  • Oral
  • Injectable
  • Nasal Sprays
  • Other

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America (United States, Canada, Mexico)
  • Europe (France, United Kingdom, Italy, Germany, Spain)
  • Asia-Pacific (China, India, Japan, Australia, South Korea)
  • South America (Brazil, Argentina, Colombia)
  • Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of major companies within the Global Acute Migraine Drugs Market.

Customization Options Available: TechSci Research offers tailored solutions for the Global Acute Migraine Drugs market report based on specific company needs.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Acute Migraine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Pain Relieving)
    • 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Acute Migraine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Migraine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Acute Migraine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Acute Migraine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Acute Migraine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Migraine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Acute Migraine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Acute Migraine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Acute Migraine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Acute Migraine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Acute Migraine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Acute Migraine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Acute Migraine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Acute Migraine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Acute Migraine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Acute Migraine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Acute Migraine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Acute Migraine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Acute Migraine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Acute Migraine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Acute Migraine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Acute Migraine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Acute Migraine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Acute Migraine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Acute Migraine Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Endo International PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. AbbVie Inc.
  • 14.3. Impax Laboratories LLC
  • 14.4. Glaxo Smith Kline PLC
  • 14.5. Astellas Pharma Inc
  • 14.6. Amgen Inc
  • 14.7. Bayer AG
  • 14.8. AstraZeneca PLC
  • 14.9. Dr. Reddy's Laboratories Ltd
  • 14.10.Eli Lilly and Company
  • 14.11.Pfizer Inc

15. Strategic Recommendations

16. About Us & Disclaimer